Riskpilot← Back to searchSign inGet full accessLUZMON MEDICAL AS
ASActiveOrg 995871238Oscars Gate 42, 0258 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20102 employees
Revenue 2024
NOK 1,6M
EBITDA margin
-355.2%
+28% vs 2023
Equity ratio
97.6%
Financial strength
Net profit 2024
NOK 73K
+100% vs 2023
| Revenue | NOK 1,6M | — |
| EBITDA | NOK -5,7M | +28% |
| Net profit | NOK 73K | +100% |
| Total assets | NOK 76,7M | -21% |
| Equity | NOK 74,9M | -21% |
| Employees | 2 | — |
Legal name
LUZMON MEDICAL AS
Org number
995871238
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
30. august 2010
Share capital
NOK 2 002 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Forskning innen helse.
Address
Oscars Gate 42, 0258 Oslo
Email
post@luzmon.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 105 | 0 | 1 607 |
| Staff expenses | −5 313 | −11 463 | −3 710 | −9 700 | −4 732 |
| EBITDA | −10 466 | −31 331 | 91 726 | −7 929 | −5 708 |
| Depreciation & amort. | −90 188 | −21 | −28 009 | −36 045 | −0 |
| EBIT | −100 654 | −31 351 | 63 717 | −43 974 | −5 708 |
| Net financials | −528 | −5 | 34 873 | 7 255 | 5 780 |
| Profit before tax | −101 182 | −31 356 | 98 590 | −36 719 | 73 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −101 182 | −31 356 | 98 590 | −36 719 | 73 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 74 176 | 71 623 | 210 844 | 97 160 | 76 728 |
| Equity | 64 537 | 64 974 | 163 563 | 94 845 | 74 917 |
| Long-term debt | 0 | 475 | 31 767 | 0 | 0 |
| Short-term debt | 9 638 | 6 174 | 15 514 | 2 316 | 1 811 |
| Total debt | 9 638 | 6 649 | 47 281 | 2 316 | 1 811 |
EBITDA margin
-355.2%
This company
15.8%
Market median
-2348% vs market
20202024
Equity ratio
97.6%
This company
38.2%
Market median
+155% vs market
20202024
Return on equity
0.1%
This company
18.4%
Market median
-99% vs market
20202024
Net profit margin
4.5%
This company
8.1%
Market median
-44% vs market
20202024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20202024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LM Chief Executive Officer | Chief Executive Officer | 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2023 | |
| Former (2) | ||
| Board of Directors | 2018 – 2023 | |
| Board of Directors | 2018 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Luzmon Holding As
LUZMON MEDICAL AS Board members of LUZMON MEDICAL AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Louise Mohn | Chief Executive Officer | 0 companies |
| Ole Per Måløy | Board of Directors | 0 companies |
| Houtan Houshangi | Board of Directors | 0 companies |
| Trond Mohn | Board of Directors | 0 companies |